Tomioka Haruaki, Tatano Yutaka, Shimizu Toshiaki, Sano Chiaki
Department of Basic Medical Science for Nursing, Department of Primary Education, Yasuda Women's University, Hiroshima 731-0153, Japan.
Department of Microbiology and Immunology, Shimane University School of Medicine, Izumo 693-8501, Japan.
Medicines (Basel). 2019 Jun 19;6(2):67. doi: 10.3390/medicines6020067.
The high incidence of tuberculosis (TB) in developing countries, the resurgence of TB in industrialized countries, and the worldwide increase in the prevalence of complex infections are important global health concerns. However, the development of novel antimycobacterial drugs is currently making very slow progress. Therefore, it is considered that devising improved administration protocols for clinical treatment against intractable mycobacteriosis using existing chemotherapeutics is more practical than awaiting the development of new antimycobacterial drugs. The regulation of host immune responses using immunoadjunctive agents may increase the efficacy of antimicrobial treatment against mycobacteriosis. In particular, the mild and long-term up-regulation of host immune reactions against mycobacterial pathogens using herbal medicines may be beneficial for such immunoadjunctive therapy. This review focuses on the current status regarding basic and clinical studies on protocols using herbal medicines, including medicinal plants, useful for the clinical treatment of intractable mycobacterial infections.
发展中国家结核病(TB)的高发病率、工业化国家结核病的再度流行以及全球范围内复杂感染患病率的上升,都是重要的全球卫生问题。然而,新型抗分枝杆菌药物的研发目前进展非常缓慢。因此,人们认为,与等待新型抗分枝杆菌药物的研发相比,设计使用现有化疗药物治疗难治性分枝杆菌病的改进给药方案更为实际。使用免疫辅助剂调节宿主免疫反应可能会提高抗分枝杆菌病抗菌治疗的疗效。特别是,使用草药对宿主针对分枝杆菌病原体的免疫反应进行温和且长期的上调,可能有利于这种免疫辅助治疗。本综述重点关注了使用草药(包括药用植物)治疗难治性分枝杆菌感染的方案的基础和临床研究现状。